Soyon Ahn is a neuroscientist whose research interests lie in understanding the role of the dopamine system in the healthy brain, and how dysfunction or degeneration of this system leads to psychiatric and neurological illness. Specifically, her goals are to identify and develop novel drug treatments for diseases of the dopamine system, such as Parkinson’s disease.
She is a faculty member in the Department of Psychiatry at UBC, and a member of the Society for Neuroscience and the Canadian Association for Neuroscience. She holds a BSc from McGill University and obtained her PhD in Neuroscience at UBC.
Soyon joined C3’s Board of Directors in July 2013.